Immutep LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ

24 Oct 2025

IMMP

Immutep LTD

20-F: Immutep Advances LAG-3 Pipeline Amid Rising R&D Costs

Immutep Limited reported increased net losses for fiscal year 2025 due to expanded clinical trial activities, while advancing its lead LAG-3 immunotherapy candidates through late-stage development and securing new patents.

NASDAQ

22 Oct 2024

IMMP

Immutep LTD

20-F: Immutep Limited Reports Financial Results and Provides Business Update in Annual 20-F Filing

Immutep Limited's 20-F filing details the company's financial performance, ongoing clinical trials, and intellectual property, highlighting a net loss for fiscal year 2024 and continued investment in research and development.